Schonfeld Strategic Advisors LLC Has $2.91 Million Stock Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Schonfeld Strategic Advisors LLC boosted its stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 1,960.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 533,643 shares of the company's stock after acquiring an additional 507,743 shares during the period. Schonfeld Strategic Advisors LLC owned 0.21% of Maravai LifeSciences worth $2,908,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Performa Ltd US LLC lifted its position in shares of Maravai LifeSciences by 614.3% during the fourth quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock worth $27,000 after purchasing an additional 4,300 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in shares of Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company's stock valued at $38,000 after acquiring an additional 6,000 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Maravai LifeSciences by 3,541.4% during the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company's stock valued at $56,000 after purchasing an additional 9,916 shares during the last quarter. Cibc World Markets Corp acquired a new position in shares of Maravai LifeSciences in the 4th quarter valued at about $56,000. Finally, Atria Investments Inc bought a new position in Maravai LifeSciences in the fourth quarter worth about $58,000. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Price Performance

NASDAQ:MRVI traded down $0.08 during midday trading on Friday, hitting $1.99. 2,210,332 shares of the stock were exchanged, compared to its average volume of 2,332,700. The company has a market capitalization of $506.13 million, a price-to-earnings ratio of -1.21 and a beta of 0.19. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. Maravai LifeSciences Holdings, Inc. has a one year low of $1.67 and a one year high of $11.56. The business has a 50-day moving average price of $2.17 and a two-hundred day moving average price of $4.21.

Analysts Set New Price Targets

MRVI has been the topic of several recent research reports. UBS Group cut their price target on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a report on Friday, March 21st. Morgan Stanley dropped their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Tuesday, March 25th. Stifel Nicolaus set a $5.00 price objective on shares of Maravai LifeSciences in a research report on Friday, March 21st. Bank of America dropped their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Finally, Robert W. Baird cut Maravai LifeSciences from an "outperform" rating to a "neutral" rating and cut their price target for the company from $9.00 to $3.00 in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $6.34.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.